Insight Molecular Diagnostics Inc. (IMDX) Fair Value 2026

IMDX · Diagnostics & Research ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.1 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (32/100)

Quick Summary — As of 2026-08-27, Insight Molecular Diagnostics Inc. (IMDX) trades at $4.29. QOC: 6.1/10. Value Trap Risk: 32/100 (LOW). 0/13 models active.

Key Facts

Ticker
IMDX
Price
$4.29
Quality Score
6.1/10
Value Trap Risk
32/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give IMDX?

0 Intrinsic Value Models vs. Current Price ($4.29)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Insight Molecular Diagnostics Inc. (IMDX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Insight Molecular Diagnostics Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About IMDX?

0 of 13 models are currently active for IMDX. See which stocks rank higher →

How Does IMDX Rank in Diagnostics & Research?

Among 52 Diagnostics & Research stocks, IMDX ranks #37 by Quality of Company score. CirclFi's QOC score of 6.1/10 evaluates 32 fundamental signals. A score of 6.1 indicates above-average quality.

Insight Molecular Diagnostics Inc.'s positioning within the Diagnostics & Research segment means that pipeline depth and stage distribution plays an outsized role in fundamental analysis. The sector's unique characteristics — including therapeutic area leadership — shape both the opportunity set and risk profile.

Is IMDX a Value Trap?

CirclFi's Value Trap algorithm assigns IMDX a score of 32/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Insight Molecular Diagnostics Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Insight Molecular Diagnostics Inc. earns a quality score of 6.1/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every IMDX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Insight Molecular Diagnostics Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Diagnostics & Research Stocks Should You Also Analyze?

11 related Diagnostics & Research stocks with 13-model coverage

GRALGRAIL, Inc.QOC 6.2QUCYQuantum Cyber N.V.QOC 5.6BDSXBiodesix, Inc.QOC 6.3OPKOPKO Health, Inc.QOC 5.6AWHLAspira Women's Health Inc.QOC 6.4XWELXWELL, Inc.QOC 5.5ICLRICON Public Limited CompanyQOC 2.8DGXQuest Diagnostics IncorporatedQOC 7.9FLGTFulgent Genetics, Inc.QOC 7.0IDXXIDEXX Laboratories, Inc.QOC 9.5MEDPMedpace Holdings, Inc.QOC 9.3

Read investment analysis: GRAL · QUCY · BDSX · OPK · AWHL · XWEL · ICLR · DGX · FLGT · IDXX · MEDP

Which Other Stocks Have a Similar Quality Score to IMDX?

7 companies across all industries closest to IMDX’s Quality of Company score of 6.1/10.

YXTYXT.COM Group Holding LimitedQOC 6.1MCTACharming Medical LimitedQOC 6.1IONQIonQ, Inc.QOC 6.1GHIGreystone Housing Impact Investors LPQOC 6.1CABOCable One, Inc.QOC 6.1TICTIC Solutions, Inc.QOC 6.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: YXT · MCTA · IONQ · GHI · CABO · TIC · NVDA

What Else Do Investors Ask About Insight Molecular Diagnostics Inc.’s Valuation?

What is Insight Molecular Diagnostics Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Insight Molecular Diagnostics Inc. (IMDX). The Quality of Company score is 6.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is IMDX overvalued or undervalued right now?

At $4.29, 0 of 0 active models suggest IMDX may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Insight Molecular Diagnostics Inc.'s business model in Diagnostics & Research.

What does a Quality of Company score of 6.1 mean for IMDX?

Insight Molecular Diagnostics Inc.'s QOC of 6.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on IMDX?

CirclFi analyzes IMDX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is IMDX a value trap in 2026?

Insight Molecular Diagnostics Inc.'s Value Trap score is 32/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Insight Molecular Diagnostics Inc. (IMDX) a Quality of Company score of 6.1/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/IMDX/ · Methodology
Primary sources for this IMDX valuation
  • Financial statements: Insight Molecular Diagnostics Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001642380) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for IMDX as of ; valuations recomputed .